Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy - New Zealand
doi 10.2147/lctt.s16310
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Pcn76 - Budget Impact Analysis of Afatinib for the First-Line Treatment of Advanced or Metastatic Non–small-Cell Lung Cancer in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Advanced Non-Small Cell Lung Cancer in Elderly Patients

Breathe
PulmonaryRespiratory Medicine
2012English

Single‐Agent Paclitaxel in the Treatment of Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1999English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

New Developments in the Treatment of Advanced Squamous Cell Lung Cancer: Focus on Afatinib

OncoTargets and Therapy
OncologyPharmacology
2017English

Clinical Efficacy and Safety of Afatinib in the Treatment of Non-Small-Cell Lung Cancer in Chinese Patients

OncoTargets and Therapy
OncologyPharmacology
2018English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy